All lobbying filings

THE WASHINGTON TAX & PUBLIC POLICY GROUP

THE WASHINGTON TAX & PUBLIC POLICY GROUP filed a Q3 report for ALLIANCE FOR BIOPHARMACEUTICAL COMPETITIVENESS AND INNOVATION on October 16, 2026, reporting $400,000 in lobbying income.

Lobbying for ALLIANCE FOR BIOPHARMACEUTICAL COMPETITIVENESS AND INNOVATION · Biopharmaceutical industry

All filings by THE WASHINGTON TAX & PUBLIC POLICY GROUP · Everything ALLIANCE FOR BIOPHARMACEUTICAL COMPETITIVENESS AND INNOVATION has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 16, 2026

Income

$400,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 3

GREGORY NICKERSON

Previously held: Tax Counsel, Ways and Means Committee; Staff Director, Ways and Means Select Revenue Measures Subcommittee
ZACHARY AUSTIN PRICE

Previously held: Staff Assistant to Sen. Coats
JAMES MAX PEDROTTI New on this filing

Previously held: Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Deputy Chief of Staff to Rep. Carol Miller

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Taxation/Internal Revenue Code

Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations, agreements, implementation, and reporting related to the taxation of global income. Issues related to the taxation of intellectual property income. Issues related to foreign country tax administration and extraterritorial taxes. Issues related to IRC sections 11, 41 and 174, 45C, 55, 56A, and 59, 59A, 163(j), 250, 951A, 954(d) and 954(e), and 960(d)(2). (H.R. 10431)

Bills named in this filing 1

H.R. 10431
U.S. Innovation and Global Competitiveness Act of 2026

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.